文献速递头颈部肿瘤放疗

晚期HPV阴性头颈癌根治性铂类放化疗后的疾病结局及相关因素

Disease outcome and associated factors after definitive platinum based chemoradiotherapy for advanced stage HPV-negative head and neck cancer.
PubMed 文献 · Radiother Oncol · 2022-08-13

多中心回顾性队列纳入2009年1月至2017年8月接受根治性顺铂同步放化疗的513例HPV阴性晚期(III-IV期)头颈鳞癌患者,66%完成计划周期、75%累积顺铂剂量达≥200 mg/m2;5年总生存率47%,喉癌生存更好(p=0.02);含临床变量与顺铂剂量的模型对总生存的关联强于TNM分期(C-index 0.68 vs 0.55)。

要点

  • 513例中66%完成计划周期、75%累积顺铂剂量≥200 mg/m2。
  • 5年总生存率47%,喉癌生存优于其他部位(p=0.02)。
  • 临床变量模型C-index 0.68优于TNM分期0.55。

核心结论

  • 尽管临床管理已有进展,超过三分之一的HPV阴性头颈鳞癌患者因顺铂毒性未完成放化疗方案。
  • 包含顺铂剂量等临床变量和治疗参数的模型与总生存的关联最强。
  • 作者认为鉴于顺铂毒性是完成根治性放化疗的主要障碍,有必要开发替代性低毒放射增敏剂以改善治疗结果。
  • 作者认为放疗推量技术与远处转移的关联是重要发现,需进一步研究。

研究设计与样本

  • 多中心回顾性队列研究,收集2009年1月至2017年8月接受根治性铂类同步放化疗的513例HPV阴性晚期(III-IV期)头颈鳞癌患者。
  • 基于临床参数建立预后模型并与TNM分期比较。

主要发现

  • 513例中49%为口咽肿瘤,73.3%为T3-T4b,84%有区域淋巴结受累。
  • 84%接受顺铂单药,66%完成计划周期数,75%累积顺铂剂量≥200 mg/m2。
  • 随访期间324例(63%)达到局部区域控制,与肿瘤部位无关联(p=0.48)。
  • 5年总生存率47%,喉癌生存优于其他部位(p=0.02)。
  • 临床变量模型(性别、治疗前高体重下降、N2c/N3期、顺铂剂量<200 mg/m2)与总生存的关联强于TNM分期(C-index 0.68 vs 0.55)。

关键数值与推荐

  • 完成计划周期数者占66%,累积顺铂剂量≥200 mg/m2者占75%。
  • 局部区域控制率63%(324/513),与肿瘤部位无关联(p=0.48)。
  • 5年总生存率47%,喉癌与其他部位比较p=0.02。
  • 临床变量模型C-index 0.68 vs TNM分期0.55。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Definitive concomitant cisplatin-based chemoradiotherapy (CRT) is the current gold standard for most patients with advanced stage head and neck squamous cell carcinoma (HNSCC) of the pharynx and larynx. Since previous meta-analysis on CRT outcomes in HNSCC have been reported, advances have been made in radiotherapy techniques and clinical management, while HPV-status has been identified as a strong confounding prognostic factor in oropharyngeal cancer. Here, we present real-world outcome data from a large multicenter cohort of HPV-negative advanced stage HNSCC treated with CRT using contemporary IMRT-based techniques. METHOD: Retrospective data were collected from a multicenter cohort of 513 patients treated with definitive concurrent platinum-based CRT with curative intent between January 2009 and August 2017. Only patients with HPV-negative advanced stage (III-IV) HNSCC were included. A prognostic model for outcome was developed based on clinical parameters and compared to TNM. RESULTS: Nearly half of the 513 patients (49%) had an oropharyngeal tumor, often locally advanced (73.3% T3-T4b) and with involvement of the regional lymph nodes (84%). Most patients (84%) received cisplatin as single agent. In total 66% received the planned number of cycles and 75% reached a cumulative cisplatin dose of ≥200 mg/m2. Locoregional control was achieved in 324 (63%) patients during follow-up, and no association with tumor sites was observed (p = 0.48). Overall survival at 5 year follow-up was 47%, with a better survival for laryngeal cancer (p = 0.02) compared to other sites. A model with clinical variables (gender, high pre-treatment weight loss, N2c/N3-stage and <200 mg/m2 dose of cisplatin) provided a noticeably stronger association with overall survival than TNM-staging (C- index 0.68 vs 0.55). Simultaneous Integrated Boosting (SIB) significantly outperformed Sequential Boosting (SEQ) to reduce the development of distant metastasis (SEQ vs SIB: OR 1.91 (1.11-3.26; p = 0.02). CONCLUSION: Despite advances in clinical management, more than a third of patients with HPV-negative HNSCC do not complete CRT treatment protocols due to cisplatin toxicity. A model that consists of clinical variables and treatment parameters including cisplatin dose provided the strongest association with overall survival. Since cisplatin toxicity is a major obstacle in completing definitive CRT, the development of alternative and less toxic radiosensitizers is therefore warranted to improve treatment results. The association of RT-boost technique with distant metastasis is an important finding and requires further study.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. de Roest RH, van der Heijden M, Wesseling FWR, et al. Disease outcome and associated factors after definitive platinum based chemoradiotherapy for advanced stage HPV-negative head and neck cancer. Radiother Oncol. 2022. PMID: 35973619. doi:10.1016/j.radonc.2022.08.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。